Business Context and Reporting Period
This Form 8-K reports on the reconvened 2025 Annual Meeting of Stockholders for Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc., as indicated in the metadata). The report date is December 31, 2025, covering events from the meeting originally held on December 19, 2025. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol SLRX.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
As of the record date (October 24, 2025), there were 1,051,782 shares of common stock outstanding. A quorum was established with 417,443 shares (39.7%) present. Stockholders approved the following proposals:
- Proposal 1 (Director Election): Re-elected two Class I directors (Arnold C. Hanish and William K. McVicar) to serve until 2028.
- Proposal 2 (Executive Compensation): Approved the non-binding advisory vote on named executive officer compensation.
- Proposal 3 (Auditor Ratification): Ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Key Facts for Investor Verification
- Verify the company name discrepancy: The metadata lists "Decoy Therapeutics Inc.," but the filing is for "Salarius Pharmaceuticals, Inc."
- Confirm the final vote counts for the re-elected directors and the executive compensation advisory vote.
- Note that the meeting was reconvened on December 31, 2025, following an initial date of December 19, 2025.
- Check the total number of shares outstanding (1,051,782) and the percentage of shares represented at the meeting (39.7%).